The first AD drug category consists of cholinesterase inhibitors (rivastigmine, donepezil, galantamine) that promote cholinergic neurotransmission and a N-methyl-D-aspartate receptor antagonist (memantine) that inhibits glutamatergic signaling. This evidence concerns the gene BCHE and Alzheimer disease.